<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibiotics (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibiotics (Basel)</journal-id><journal-id journal-id-type="publisher-id">antibiotics</journal-id><journal-title-group><journal-title>Antibiotics</journal-title></journal-title-group><issn pub-type="epub">2079-6382</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6022977</article-id><article-id pub-id-type="doi">10.3390/antibiotics7020036</article-id><article-id pub-id-type="publisher-id">antibiotics-07-00036</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Specificity of Induction of Glycopeptide Antibiotic Resistance in the Producing Actinomycetes</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9305-4451</contrib-id><name><surname>Binda</surname><given-names>Elisa</given-names></name><xref ref-type="aff" rid="af1-antibiotics-07-00036">1</xref><xref ref-type="aff" rid="af2-antibiotics-07-00036">2</xref></contrib><contrib contrib-type="author"><name><surname>Cappelletti</surname><given-names>Pamela</given-names></name><xref ref-type="aff" rid="af1-antibiotics-07-00036">1</xref><xref ref-type="aff" rid="af2-antibiotics-07-00036">2</xref></contrib><contrib contrib-type="author"><name><surname>Marinelli</surname><given-names>Flavia</given-names></name><xref ref-type="aff" rid="af1-antibiotics-07-00036">1</xref><xref ref-type="aff" rid="af2-antibiotics-07-00036">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4650-9449</contrib-id><name><surname>Marcone</surname><given-names>Giorgia Letizia</given-names></name><xref ref-type="aff" rid="af1-antibiotics-07-00036">1</xref><xref ref-type="aff" rid="af2-antibiotics-07-00036">2</xref><xref rid="c1-antibiotics-07-00036" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-antibiotics-07-00036"><label>1</label>Department of Biotechnology and Life Sciences, University of Insubria, via J.H. Dunant 3, 21100 Varese, Italy; <email>elisa.binda@uninsubria.it</email> (E.B.); <email>pamela.cappelletti@uninsubria.it</email> (P.C.); <email>flavia.marinelli@uninsubria.it</email> (F.M.)</aff><aff id="af2-antibiotics-07-00036"><label>2</label>The Protein Factory Research Center, Politecnico di Milano and University of Insubria, via J.H. Dunant 3, 21100 Varese, Italy</aff><author-notes><corresp id="c1-antibiotics-07-00036"><label>*</label>Correspondence: <email>giorgia.marcone@uninsubria.it</email>; Tel.: +39-0332-421332</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2018</year></pub-date><volume>7</volume><issue>2</issue><elocation-id>36</elocation-id><history><date date-type="received"><day>28</day><month>2</month><year>2018</year></date><date date-type="accepted"><day>20</day><month>4</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Glycopeptide antibiotics are drugs of last resort for treating severe infections caused by Gram-positive pathogens. It is widely believed that glycopeptide-resistance determinants (<italic>van</italic> genes) are ultimately derived from the producing actinomycetes. We hereby investigated the relationship between the antimicrobial activity of vancomycin and teicoplanins and their differential ability to induce <italic>van</italic> gene expression in <italic>Actinoplanes teichomyceticus</italic>&#x02014;the producer of teicoplanin&#x02014;and <italic>Nonomuraea gerenzanensis</italic>&#x02014;the producer of the teicoplanin-like A40926. As a control, we used the well-characterized resistance model <italic>Streptomyces coelicolor</italic>. The enzyme activities of a cytoplasmic-soluble <sc>d</sc>,<sc>d</sc>-dipeptidase and of a membrane-associated <sc>d</sc>,<sc>d</sc>-carboxypeptidase (corresponding to VanX and VanY respectively) involved in resistant cell wall remodeling were measured in the actinomycetes grown in the presence or absence of subinhibitory concentrations of vancomycin, teicoplanin, and A40926. Results indicated that actinomycetes possess diverse self-resistance mechanisms, and that each of them responds differently to glycopeptide induction. Gene swapping among teicoplanins-producing actinomycetes indicated that cross-talking is possible and provides useful information for predicting the evolution of future resistance gene combinations emerging in pathogens.</p></abstract><kwd-group><kwd>actinomycetes</kwd><kwd>glycopeptide antibiotics</kwd><kwd>teicoplanin</kwd><kwd>A40926</kwd><kwd><italic>van</italic> resistance genes</kwd></kwd-group></article-meta></front><body><sec id="sec1-antibiotics-07-00036"><title>1. Introduction</title><p>Glycopeptide antibiotics (GPAs) are drugs of last resort for treating severe infections caused by Gram-positive pathogens such as <italic>Staphylococcus aureus</italic> (SA), <italic>Enterococcus</italic> spp., and <italic>Clostridioides difficile</italic> [<xref rid="B1-antibiotics-07-00036" ref-type="bibr">1</xref>]. Clinically important GPAs include first-generation vancomycin and teicoplanin&#x02014;which, although discovered many decades ago, continue to be extensively used in clinical practice&#x02014;and second-generation telavancin, dalbavancin, and oritavancin, which were recently approved for clinical use for their increased antimicrobial potency and superior pharmacokinetic properties [<xref rid="B2-antibiotics-07-00036" ref-type="bibr">2</xref>,<xref rid="B3-antibiotics-07-00036" ref-type="bibr">3</xref>,<xref rid="B4-antibiotics-07-00036" ref-type="bibr">4</xref>]. Vancomycin and teicoplanin are natural product GPAs produced by soil-dwelling filamentous actinomycetes. Their common structural motif is a core heptapeptide scaffold containing aromatic amino acids that have undergone extensive oxidative cross-linking and decoration with different moieties, such as sugar residues, chlorine atoms and&#x02014;in case of teicoplanin&#x02014;a lipid chain. GPAs inhibit peptidoglycan (PG) synthesis by binding to the <sc>d</sc>-alanyl-<sc>d</sc>-alanine (<sc>d</sc>-Ala-<sc>d</sc>-Ala) terminus of the peptide stem of PG-precursor lipid II. The binding of GPAs to lipid II by forming five hydrogen bonds locks PG precursors, impeding subsequent cross-linking reactions [<xref rid="B5-antibiotics-07-00036" ref-type="bibr">5</xref>,<xref rid="B6-antibiotics-07-00036" ref-type="bibr">6</xref>]. Second-generation GPAs are semisynthetic derivatives of vancomycin- and teicoplanin-like molecules, where the chemical modifications were introduced outside the <sc>d</sc>-Ala-<sc>d</sc>-Ala binding pocket, mainly involving the appendage of hydrophobic aryl or acyl groups that mimic the natural lipid chain of teicoplanin. In fact, the superior antimicrobial potency of teicoplanin-like molecules is due to membrane anchoring of the hydrophobic tail, which strengthens the bond to membrane-localized lipid II [<xref rid="B7-antibiotics-07-00036" ref-type="bibr">7</xref>,<xref rid="B8-antibiotics-07-00036" ref-type="bibr">8</xref>]. Additionally, Dong et al. [<xref rid="B9-antibiotics-07-00036" ref-type="bibr">9</xref>] demonstrated that lipidation is the key functional difference between vancomycin and teicoplanin related to their differing abilities of inducing a GPA resistance response in enterococci. More recently Kwun and Hong [<xref rid="B10-antibiotics-07-00036" ref-type="bibr">10</xref>], using the harmless actinomycete <italic>Streptomyces coelicolor</italic> as a model resistance system, confirmed that teicoplanin-like derivatives are poor inducers of GPA resistance, and a lack of induction accounts for the susceptibility to these molecules.</p><p>Many different GPA-resistant phenotypes have been described in enterococci and staphylococci (for an extensive review, see Binda et al., 2014 [<xref rid="B2-antibiotics-07-00036" ref-type="bibr">2</xref>]). In the two most prominent manifestations of resistance (VanA or VanB phenotypes), the GPA-induced expression of <italic>van</italic> genes remodels the bacterial cell wall. The replacement of the dipeptide (<sc>d</sc>-Ala-<sc>d</sc>-Ala) terminus of PG precursor with the depsipeptide <sc>d</sc>-alanyl-<sc>d</sc>-lactate (<sc>d</sc>-Ala-<sc>d</sc>-Lac) reduces by 1000-fold the GPA affinity to their molecular target [<xref rid="B11-antibiotics-07-00036" ref-type="bibr">11</xref>]. Strains displaying this type of resistance are either resistant to both vancomycin and teicoplanin (VanA phenotype), or they are resistant only to vancomycin and susceptible to teicoplanin (VanB phenotype) [<xref rid="B12-antibiotics-07-00036" ref-type="bibr">12</xref>]. Although the proteins directly involved in conferring VanA resistance&#x02014;i.e., VanH, which converts pyruvate into <sc>d</sc>-lactate; VanA, a <sc>d</sc>-Ala-<sc>d</sc>-Lac ligase; and VanX, a <sc>d</sc>-Ala-<sc>d</sc>-Ala dipeptidase&#x02014;are highly homologous to their counterparts in the VanB phenotype (VanHB, VanB, VanXB), the two-component regulatory systems controlling <italic>van</italic> gene transcription (VanS/VanR in VanA phenotype and VanSB/VanRB in VanB phenotype) are only distantly related [<xref rid="B13-antibiotics-07-00036" ref-type="bibr">13</xref>]. In particular, the membrane-associated sensor domains of VanS and VanSB are unrelated in amino acid sequence, and they respond to GPAs by different mechanisms which account for the difference in induction specificity by vancomycin and teicoplanin and their semi-synthetic derivatives [<xref rid="B13-antibiotics-07-00036" ref-type="bibr">13</xref>,<xref rid="B14-antibiotics-07-00036" ref-type="bibr">14</xref>,<xref rid="B15-antibiotics-07-00036" ref-type="bibr">15</xref>]. Many efforts [<xref rid="B12-antibiotics-07-00036" ref-type="bibr">12</xref>,<xref rid="B14-antibiotics-07-00036" ref-type="bibr">14</xref>,<xref rid="B16-antibiotics-07-00036" ref-type="bibr">16</xref>,<xref rid="B17-antibiotics-07-00036" ref-type="bibr">17</xref>] have been devoted to identifying the molecular species responsible for differently inducing VanS and VanSB, but their entity and mode of action&#x02014;i.e., direct binding of the GPAs to the sensor domain or its activation by cell wall intermediates that accumulate as a result of antibiotic action&#x02014;is still being questioned.</p><p>Since it is widely believed that GPA resistance mechanisms are ultimately derived from GPA-producing actinomycetes, which use them to avoid suicide during antibiotic production [<xref rid="B2-antibiotics-07-00036" ref-type="bibr">2</xref>,<xref rid="B14-antibiotics-07-00036" ref-type="bibr">14</xref>], in this paper we investigated the specificity of induction of GPA resistance in teicoplanin- and A40926-producing actinomycetes. Teicoplanin is produced by <italic>Actinoplanes teichomyceticus</italic>, and the teicoplanin-like molecule A40926 [<xref rid="B18-antibiotics-07-00036" ref-type="bibr">18</xref>], which is the natural precursor of the second-generation dalbavancin, is produced by the recently classified <italic>Nonomuraea gerenzanensis</italic> [<xref rid="B19-antibiotics-07-00036" ref-type="bibr">19</xref>,<xref rid="B20-antibiotics-07-00036" ref-type="bibr">20</xref>]. As a control, we used the well-characterized resistance model <italic>S. coelicolor</italic>, which does not synthesize any GPA but does possess a <italic>van</italic> gene cluster conferring inducible resistance to vancomycin but not to teicoplanin, showing the features of the VanB phenotype [<xref rid="B10-antibiotics-07-00036" ref-type="bibr">10</xref>,<xref rid="B16-antibiotics-07-00036" ref-type="bibr">16</xref>,<xref rid="B21-antibiotics-07-00036" ref-type="bibr">21</xref>]. The purpose of this study was to elucidate the relationship between GPA activity and the ability to induce <italic>van</italic> gene expression in the producing actinomycetes, which are considered the evolutionary source of resistance determinants emerging in pathogens, shedding light on the possible evolution of the <italic>van</italic> gene cluster.</p></sec><sec id="sec2-antibiotics-07-00036"><title>2. Results and Discussion</title><p><xref rid="antibiotics-07-00036-t001" ref-type="table">Table 1</xref> reports the minimal inhibitory concentrations (MICs) of vancomycin, teicoplanin, and A40926 against <italic>S. coelicolor</italic>, <italic>A. teichomyceticus,</italic> and <italic>N. gerenzanensis</italic> on solid media. MICs were measured on solid media, since the standard broth dilution method used in unicellular bacteria to determine MICs by turbidity is compromised in mycelial actinomycetes by the formation of multicellular aggregates and by the coexistence of cells in different physiological states (e.g., vegetative mycelium, aerial mycelium, and spores). This is particularly true for difficult-to-cultivate nonstreptomyces actinomycetes such as <italic>Actinoplanes</italic> and <italic>Nonomuraea</italic> strains, which form compact and different-sized clumps when growing in liquid cultures.</p><p>As expected, <italic>S. coelicolor</italic> was resistant to vancomycin and susceptible to teicoplanin and A40926. Its &#x02206;<italic>vanRS</italic> mutant did not respond to vancomycin, and consequently, it was sensitive to it [<xref rid="B10-antibiotics-07-00036" ref-type="bibr">10</xref>]. For these <italic>Streptomyces</italic> strains, MICs values were slightly higher than those previously reported in a liquid medium [<xref rid="B10-antibiotics-07-00036" ref-type="bibr">10</xref>], which is likely due to the different cultivation method used. Interestingly, <italic>S. coelicolor</italic> and its &#x02206;<italic>vanRS</italic> mutant were equally sensitive to bacitracin and ramoplanin, which are antibiotics structurally unrelated to GPAs that inhibit the late steps of PG synthesis by a diverse mode of action [<xref rid="B22-antibiotics-07-00036" ref-type="bibr">22</xref>,<xref rid="B23-antibiotics-07-00036" ref-type="bibr">23</xref>], evidently not mediated by VanS interaction.</p><p><italic>A. teichomyceticus</italic> was resistant to all the GPAs tested (<xref rid="antibiotics-07-00036-t001" ref-type="table">Table 1</xref>), although its chromosome harbours a canonical <italic>vanHAX</italic> gene cluster including the <italic>vanRS</italic> two component-regulatory system associated with the teicoplanin biosynthetic genes [<xref rid="B24-antibiotics-07-00036" ref-type="bibr">24</xref>]. In this actinomycete, <italic>van</italic> genes are expressed constitutively, even in the absence of the antibiotic, making the cells intrinsically resistant to GPAs [<xref rid="B24-antibiotics-07-00036" ref-type="bibr">24</xref>,<xref rid="B25-antibiotics-07-00036" ref-type="bibr">25</xref>].</p><p>In contrast, the A40926-producing strain <italic>N. gerenzanensis</italic> was resistant to vancomycin (less than <italic>A. teichomyceticus</italic> and <italic>S. coelicolor</italic>) but sensitive to teicoplanin and to its own product, albeit at a lower extent. As previously described [<xref rid="B26-antibiotics-07-00036" ref-type="bibr">26</xref>], <italic>N. gerenzanensis</italic> does not possess a <italic>vanHAX</italic> gene cluster, and the only known mechanism of resistance relies on the action of a VanY metallo-<sc>d</sc>,<sc>d</sc>-carboxypeptidase (named VanYn) that hydrolyses the C-terminal <sc>d</sc>-Ala residue of PG pentapeptide precursors. Interestingly, the well-characterized VanA and VanB type enterococci possess, in addition to <italic>vanHAX</italic> genes, an extra <italic>vanY</italic> gene that plays an ancillary unessential role in conferring glycopeptide resistance [<xref rid="B27-antibiotics-07-00036" ref-type="bibr">27</xref>]. Upon vancomycin induction, enterococcal VanX cleaves any residual cytoplasmic <sc>d</sc>-Ala-<sc>d</sc>-Ala dipeptide, ensuring that the newly formed PG precursors terminate mostly in <sc>d</sc>-Ala-<sc>d</sc>-Lac, whereas VanY just acts on PG precursors that have escaped VanX hydrolysis and converts them into GPA-resistant tetrapeptides [<xref rid="B27-antibiotics-07-00036" ref-type="bibr">27</xref>]. The integration of the pST30 plasmid containing the complete <italic>vanRSHAX</italic> gene cluster from <italic>A. teichomyceticus</italic> [<xref rid="B25-antibiotics-07-00036" ref-type="bibr">25</xref>,<xref rid="B28-antibiotics-07-00036" ref-type="bibr">28</xref>] into the <italic>N. gerenzanensis</italic> chromosome, consistently rendered the host strain more resistant to teicoplanin and A40926 in comparison to the parental strain harbouring only the <italic>vanY</italic> gene (<xref rid="antibiotics-07-00036-t001" ref-type="table">Table 1</xref>), confirming the role of <italic>vanHAX</italic> genes in conferring high GPA resistance.</p><p>In contrast to <italic>S. coelicolor</italic>, both <italic>A. teichomyceticus</italic> and <italic>N. gerenzanensis</italic> were intrinsically resistant to both bacitracin and ramoplanin. This last result merits further investigation, although it is well-known that PG structure and density, and consequently antibiotic resistance profile, might dramatically vary among different genera of actinomycetes [<xref rid="B19-antibiotics-07-00036" ref-type="bibr">19</xref>,<xref rid="B29-antibiotics-07-00036" ref-type="bibr">29</xref>,<xref rid="B30-antibiotics-07-00036" ref-type="bibr">30</xref>].</p><p>To determine the correlation between the antimicrobial activity of the GPAs and their ability to induce the <italic>van</italic> resistance system in actinomycetes, we followed the enzyme activities corresponding to either VanX or VanY peptidases in cells growing in liquid culture in the presence or absence of subinhibitory concentrations of GPAs (<xref ref-type="fig" rid="antibiotics-07-00036-f001">Figure 1</xref> and <xref ref-type="fig" rid="antibiotics-07-00036-f002">Figure 2</xref>). The <sc>d</sc>,<sc>d</sc>-dipeptidase activity of VanX (<xref ref-type="fig" rid="antibiotics-07-00036-f001">Figure 1</xref>) and the <sc>d</sc>,<sc>d</sc>-carboxypeptidase activity of VanY (<xref ref-type="fig" rid="antibiotics-07-00036-f002">Figure 2</xref>) were measured by determining the amount of <sc>d</sc>-Ala released from the hydrolysis of the <sc>d</sc>-Ala-<sc>d</sc>-Ala dipeptide and of the N<sub>&#x003b5;</sub>-acetyl-<sc>l</sc>-Lys-<sc>d</sc>-Ala-<sc>d</sc>-Ala tripeptide, respectively. <sc>d</sc>-Ala release was measured by using a <sc>d</sc>-amino acid oxidase coupled to a peroxidase [<xref rid="B25-antibiotics-07-00036" ref-type="bibr">25</xref>,<xref rid="B31-antibiotics-07-00036" ref-type="bibr">31</xref>]. As in the case of enterococci [<xref rid="B27-antibiotics-07-00036" ref-type="bibr">27</xref>], VanX activity was detectable in the cytoplasmic fractions of <italic>S. coelicolor</italic>, <italic>S. coelicolor</italic> &#x02206;<italic>vanRS</italic>, <italic>A. teichomyceticus</italic>, and <italic>N. gerenzanensis</italic> pST30 (<xref ref-type="fig" rid="antibiotics-07-00036-f001">Figure 1</xref>), and it was specific for the hydrolysis of <sc>d</sc>,<sc>d</sc>-dipeptides, being inactive on the ester <sc>d</sc>-Ala-<sc>d</sc>-Lac and on dipeptides substituted at the C or N terminus (data not shown). No VanX activity was detectable in <italic>N. gerenzanensis</italic> cytoplasmic fractions (see <xref ref-type="app" rid="app1-antibiotics-07-00036">Table S1 Supplementary Material</xref>). Alternatively, VanY activity was detectable only in the membrane fractions of <italic>N. gerenzanensis</italic> and in its recombinant-derived <italic>N. gerenzanensis</italic> pST30 strain (<xref ref-type="fig" rid="antibiotics-07-00036-f002">Figure 2</xref>), consistent with the predicted VanY N-terminal structure, which contains a hydrophobic domain [<xref rid="B31-antibiotics-07-00036" ref-type="bibr">31</xref>]. No VanY activity was detectable in <italic>S. coelicolor</italic>, <italic>S. coelicolor</italic> &#x02206;<italic>vanRS</italic>, and <italic>A. teichomyceticus</italic> (see <xref ref-type="app" rid="app1-antibiotics-07-00036">Table S1 Supplementary Material</xref>).</p><p>In <italic>S. coelicolor</italic> and <italic>S. coelicolor</italic> &#x02206;<italic>vanRS,</italic> basal VanX activity (without any GPA addition) reached the maximum value within the 24 h of growth. When <italic>S. coelicolor</italic> parental strain was grown in the presence of subinhibitory concentrations of vancomycin (10 &#x000b5;g/mL), teicoplanin (0.75 &#x000b5;g/mL), and A40926 (0.75 &#x000b5;g/mL), only vancomycin induced an increase in VanX activity, and the level of enzyme activity doubled within the first 24 h from the induction (<xref ref-type="fig" rid="antibiotics-07-00036-f001">Figure 1</xref>). The addition of ramoplanin and bacitracin (both added at 0.45 &#x000b5;g/mL) did not show any effect on VanX activity (data not shown), thus indicating the specificity of vancomycin induction. Moreover, the addition of subinhibitory concentrations of vancomycin (in this case 0.6 &#x000b5;g /mL), teicoplanin (0.75 &#x000b5;g/mL), A40926 (0.75 &#x000b5;g/mL), and ramoplanin and bacitracin (both added at 0.45 &#x000b5;g/mL) to <italic>S. coelicolor</italic> &#x02206;<italic>vanRS</italic> did not induce any increase in VanX activity, confirming the role of VanS in responding to vancomycin induction (<xref ref-type="fig" rid="antibiotics-07-00036-f001">Figure 1</xref>).</p><p>In <italic>A. teichomyceticus</italic>, basal VanX activity (without any GPA addition) reached the maximum value after 48 h of growth. No significant variation in VanX activity was detectable following the addition of 45 &#x000b5;g/mL of vancomycin, of 10 &#x000b5;g/mL of teicoplanin, or of 15 &#x000b5;g/mL of A40926 (<xref ref-type="fig" rid="antibiotics-07-00036-f001">Figure 1</xref>). As expected, the MICs of GPAs measured on <italic>A. teichomyceticus</italic> after 48 and 72 h of growth in the presence of teicoplanin were the same as reported in <xref rid="antibiotics-07-00036-t001" ref-type="table">Table 1</xref> (see <xref ref-type="app" rid="app1-antibiotics-07-00036">Table S2 in Supplementary Material</xref>). These results are in agreement with the constitutive expression of <italic>vanHAX</italic> genes that, according to Beltrametti et al. [<xref rid="B24-antibiotics-07-00036" ref-type="bibr">24</xref>], is due to an impaired phosphatase function of the mutated VanS, which is consequently locked in the &#x0201c;on&#x0201d; state in this organism [<xref rid="B14-antibiotics-07-00036" ref-type="bibr">14</xref>]. The addition of ramoplanin and bacitracin did not exert any specific effect on the VanX activity in <italic>A. teichomyceticus</italic> (data not shown).</p><p>Interesting is what occurred in the recombinant strain <italic>N. gerenzanensis</italic> pST30 that, in addition to <italic>vanYn</italic>, also harbours the heterologous <italic>vanX</italic> from <italic>A. teichomyceticus</italic>. In this strain, the basal <sc>d</sc>,<sc>d</sc>-dipeptidase activity of VanX reached the maximum value after 72 h of growth. VanX activity was induced by 10 &#x000b5;g/mL of vancomycin, by 1.75 &#x000b5;g/mL of teicoplanin, and by 10 &#x000b5;g/mL of A40926, albeit with different kinetics and intensity (<xref ref-type="fig" rid="antibiotics-07-00036-f001">Figure 1</xref>). When the <italic>A. teichomyceticus vanRSHAX</italic> genes were integrated into the host genome, VanX activity was not longer under the control of the parental <italic>vanRS</italic> but became inducible by GPAs, undergoing regulation by a still-unknown circuit present in <italic>N. gerenzanensis</italic>, which responds to subinhibitory concentrations of vancomycin (within the 48 h of growth), A40926 (within the 72 h), and, albeit to less extent, teicoplanin (within the 48 h) (<xref ref-type="fig" rid="antibiotics-07-00036-f001">Figure 1</xref>).</p><p>To shed light on the specificity of induction of GPA resistance in <italic>N. gerenzanensis</italic>, we compared the VanY activity in <italic>N. gerenzanensis</italic> and in its recombinant strain <italic>N. gerenzanensis</italic> pST30 when grown in the absence or presence of GPAs (<xref ref-type="fig" rid="antibiotics-07-00036-f002">Figure 2</xref>). In both the strains, basal VanY activity reached its maximum activity after 72 h of growth. Upon induction with 10 &#x000b5;g/mL of vancomycin, 0.45 &#x000b5;g/mL of teicoplanin, or 2 &#x000b5;g/mL of A40926, VanY activity in the parental strain increased within the first 24 h (<xref ref-type="fig" rid="antibiotics-07-00036-f002">Figure 2</xref>), suggesting that VanY-based resistance was induced by the exposure to the three GPAs. As expected, MICs of GPAs measured on <italic>N. gerenzanensis</italic> after 48 and 72 h of growth in the presence of A40926 increased, as reported in <xref ref-type="app" rid="app1-antibiotics-07-00036">Table S2 of Supplementary Material</xref>. Again, the addition of ramoplanin and bacitracin did not influence the activity profile (data not shown). Surprisingly, the membrane-associated VanY activity in <italic>N. gerenzanensis</italic> pST30 was significantly induced only by vancomycin, and its detection was delayed in comparison to the parental strain, reaching its maximum value after 96 h of growth (<xref ref-type="fig" rid="antibiotics-07-00036-f002">Figure 2</xref>). In the presence of A40926 and teicoplanin, the VanY activity was comparable to the basal level previously observed in the noninduced recombinant strain (<xref ref-type="fig" rid="antibiotics-07-00036-f002">Figure 2</xref>). Intriguingly, these data suggest that swapping heterologous <italic>A. teichomyceticus</italic> genes in <italic>N. gerenzanensis</italic> pST30 did alter the specificity of induction of the homologous VanY activity, although the heterologous VanX activity responded to induction by the three GPAs as the VanY activity did in the parental strain. It seems that in the presence of the heterologous VanX dipeptidase, homologous VanY carboxyesterase tends to play an auxiliary role as it occurs in VanA and VanB enterococci [<xref rid="B21-antibiotics-07-00036" ref-type="bibr">21</xref>]. Irrespective of this finding, further investigations on the still-unknown regulatory genes controlling GPA resistance in <italic>N. gerenzanensis</italic> are needed to better explain these diverse responses to GPA induction. In a previous &#x02018;<italic>van</italic> genes&#x02019; swapping experiment conducted by Hutchings et al., 2006, introducing the <italic>Streptomyces toyocaensis</italic> VanRS signal transduction system into <italic>S. coelicolor</italic> &#x02206;<italic>vanRS</italic> switched inducer specificity to that of <italic>S. toyocaensis</italic>, whose resistant genes are induced by A47934 but not by vancomycin [<xref rid="B21-antibiotics-07-00036" ref-type="bibr">21</xref>]. The authors concluded that the inducer specificity was determined by the origin of VanS/VanR [<xref rid="B21-antibiotics-07-00036" ref-type="bibr">21</xref>]. More recently, Kilian et al. reported that the VanRS homologous two-component system VnlRS of <italic>Amycolatopsis balhimycina</italic> (which produces the vancomycin-type balhimycin) activated the transcription of the <italic>vanHAX</italic> genes in <italic>S. coelicolor</italic>, but not in <italic>A. balhimycina</italic> [<xref rid="B32-antibiotics-07-00036" ref-type="bibr">32</xref>]. Surprisingly, the introduction of VnlRS from <italic>A. balhimycina</italic> into <italic>S. coelicolor</italic> induced teicoplanin resistance, most likely by activating further unknown genes required for teicoplanin resistance [<xref rid="B32-antibiotics-07-00036" ref-type="bibr">32</xref>]. Although two members of a putative VanRS-like two-component signal transduction system were previously identified in the A40926 biosynthetic cluster in <italic>N. gerenzanensis</italic> [<xref rid="B33-antibiotics-07-00036" ref-type="bibr">33</xref>], their role in controlling the VanY-based self-resistance mechanism and in responding to GPA induction is still unveiled and merit further investigations.</p></sec><sec id="sec3-antibiotics-07-00036"><title>3. Materials and Methods</title><sec id="sec3dot1-antibiotics-07-00036"><title>3.1. Strains and Media</title><p><italic>S. coelicolor</italic> A3(2) was a gift from Mervyn Bibb, John Innes Institute, Norwich, UK [<xref rid="B34-antibiotics-07-00036" ref-type="bibr">34</xref>]. The &#x00394;<italic>vanRS</italic> mutant of <italic>S. coelicolor</italic> was generously donated by Hee-Jeon Hong, University of Cambridge, UK [<xref rid="B21-antibiotics-07-00036" ref-type="bibr">21</xref>]. <italic>Streptomyces</italic> spp. strains were maintained as spores in 10% (<italic>v/v</italic>) glycerol and propagated in MS agar media [<xref rid="B34-antibiotics-07-00036" ref-type="bibr">34</xref>]. Liquid media for streptomycetes were YEME [<xref rid="B34-antibiotics-07-00036" ref-type="bibr">34</xref>] and BTSB (Difco). Colonies were picked up from agar plates and inoculated into 300 mL Erlenmeyer flasks containing 50 mL of YEME. Flask cultures were incubated on a rotary shaker at 200 rpm and 28 &#x000b0;C.</p><p><italic>N. gerenzanensis</italic> ATCC 39727 [<xref rid="B19-antibiotics-07-00036" ref-type="bibr">19</xref>], its recombinant strain <italic>N. gerenzanensis</italic> pST30 [<xref rid="B25-antibiotics-07-00036" ref-type="bibr">25</xref>], and <italic>A. teichomyceticus</italic> ATCC 31121 [<xref rid="B35-antibiotics-07-00036" ref-type="bibr">35</xref>] were maintained as lyophilized master cell banks (MCBs). The mycelium from the MCBs was streaked on slants of a salt medium (SM) [<xref rid="B34-antibiotics-07-00036" ref-type="bibr">34</xref>] solidified with agar (15 g/liter). After its growth, the mycelium from a slant was homogenized in 10 mL of 0.9% (<italic>w</italic>/<italic>v</italic>) NaCl, inoculated into liquid SM, grown for 96 h at 28 &#x000b0;C with aeration, and stored as a working cell bank (WCB) in 1.5 mL cryovials at &#x02212;80 &#x000b0;C. One vial was used to inoculate each 300 mL Erlenmeyer flask containing 50 mL VSP medium [<xref rid="B26-antibiotics-07-00036" ref-type="bibr">26</xref>], and the flasks were incubated at 28 &#x000b0;C, with shaking at 200 rpm. Previous HPLC data showed that no A40926 or teicoplanin production occurred in this vegetative medium [<xref rid="B26-antibiotics-07-00036" ref-type="bibr">26</xref>,<xref rid="B35-antibiotics-07-00036" ref-type="bibr">35</xref>]. In the case of <italic>N. gerenzanensis</italic> pST30, the VSP medium was added with 50 &#x000b5;g/mL apramycin to maintain plasmid selection. Surface cultures were grown on V0.1 agar [<xref rid="B26-antibiotics-07-00036" ref-type="bibr">26</xref>]. All medium components were from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise stated.</p></sec><sec id="sec3dot2-antibiotics-07-00036"><title>3.2. Induction Experiments</title><p><italic>S. coelicolor</italic> A3(2), its &#x00394;<italic>vanRS</italic> mutant, <italic>A. teichomyceticus</italic> ATCC 31121, <italic>N. gerenzanensis</italic> ATCC 39727, and <italic>N. gerenzanensis</italic> pST30 were grown as described above. Vancomycin, teicoplanin, A40926, bacitracin, and ramoplanin (all from Sigma-Aldrich) were dissolved in MilliQ water and sterilized by filtration using 0.22 &#x000b5;m filters. Antibiotics were added to the cultures at the moment of inoculation using concentrations calculated as the half-point of MICs (see below and <xref rid="antibiotics-07-00036-t001" ref-type="table">Table 1</xref>), except for vancomycin (10 &#x000b5;g/mL) in <italic>S. coelicolor</italic> A3(2), as reported by Kwun et al. [<xref rid="B10-antibiotics-07-00036" ref-type="bibr">10</xref>]. At these concentrations, growth curves of noninduced and induced strains were overlapping.</p></sec><sec id="sec3dot3-antibiotics-07-00036"><title>3.3. MIC Determination</title><p>Cryovials of WCBs were thawed at room temperature and used to inoculate a VSP medium for <italic>Nonomuraea</italic> spp. and <italic>Actinoplanes</italic> spp. or YEME for <italic>Streptomyces</italic> spp. in the presence or the absence of GPAs. The strains were grown to exponential phase (approximately 72 h) at 28 &#x000b0;C with shaking. The mycelium was harvested by centrifugation, suspended in 0.9% (<italic>w</italic>/<italic>v</italic>) NaCl, and fragmented by sonication with a Vibracell Albra sonicator 400 W [<xref rid="B26-antibiotics-07-00036" ref-type="bibr">26</xref>]. A suspension of sonicated hyphae (corresponding to 10<sup>7</sup> CFU) was seeded onto V0.1 (<italic>Nonomuraea</italic> spp. and <italic>Actinoplanes</italic> spp.) or MS (<italic>Streptomyces</italic> spp.) agar plates supplemented with increasing concentrations of the following antibiotics: 0 to 100 &#x000b5;g/mL vancomycin in 10-&#x000b5;g/mL increments; 0 to 2 &#x000b5;g/mL teicoplanin in 0.1-&#x000b5;g/mL increments or 0 to 40 &#x000b5;g/mL teicoplanin in 10-&#x000b5;g/mL increments depending on the strain; and 0 to 5 &#x000b5;g/mL or 5 to 50 &#x000b5;g/mL A40926, depending on the strain, in 0.5-&#x000b5;g/mL or 2.5-&#x000b5;g/mL increments. The plates were dried and then incubated at 28 &#x000b0;C. MIC values were determined as the lowest antibiotic concentrations that inhibited visible growth after 10 days of incubation.</p></sec><sec id="sec3dot4-antibiotics-07-00036"><title>3.4. <sc>d,d</sc>-dipeptidase and <sc>d,d</sc>-carboxypeptidase Assays</title><p>Cells were harvested by centrifugation at 3600&#x000d7; <italic>g</italic> for 20 min at 4 &#x000b0;C, and then they were suspended in 2 mL of 0.9% (<italic>w</italic>/<italic>v</italic>) NaCl per gram of cells (wet weight). All of the following manipulations were conducted at 0 to 4 &#x000b0;C. The mycelium was fragmented by sonication with a Sonics Vibracell VCX 130. Sonication was carried out for 5 min on ice, with cycles of 30 s with an amplitude of 90% (90% of 60 Hz), with breaks of 10 s. The samples were then centrifuged at 39,000&#x000d7; <italic>g</italic> for 15 min, and the supernatants (cytoplasmic fractions) were collected. An alkaline extraction of the pellets (cell debris and membrane fractions) was carried out by adapting a protocol developed previously for extracting membrane-bound proteins [<xref rid="B25-antibiotics-07-00036" ref-type="bibr">25</xref>,<xref rid="B36-antibiotics-07-00036" ref-type="bibr">36</xref>]. The sedimented pellets were resuspended in ice-cold distilled water containing proteinase inhibitors (0.19 mg/mL phenylmethanesulfonyl fluoride and 0.7 &#x000b5;g/mL pepstatin, both purchased from Sigma-Aldrich), and then, immediately before centrifugation (28,000&#x000d7; <italic>g</italic> for 15 min at 4 &#x000b0;C), the pH was adjusted to 12 by adding an appropriate volume of 2.5 N NaOH. Immediately after centrifugation, the supernatants were neutralized to pH 7 by adding 0.5 M sodium acetate (pH 5.4). Enzymatic activities in the supernatant (cytoplasmic fractions) and in the resuspended insoluble fractions (membranes) were assayed as reported previously [<xref rid="B36-antibiotics-07-00036" ref-type="bibr">36</xref>] by measuring the release of <sc>d</sc>-Ala from commercially available dipeptide (<sc>d</sc>-Ala-<sc>d</sc>-Ala, 10 mM; Sigma-Aldrich) and tripeptide (N<sub>&#x003b5;</sub>-acetyl-<sc>l</sc>-Lys-<sc>d</sc>-Ala-<sc>d-</sc>Ala, 10 mM; Sigma-Aldrich). <sc>d</sc>,<sc>d</sc>-carboxypeptidase activity was confirmed using 10 mM UDP-MurNAc-<sc>l</sc>-Ala-<sc>d</sc>-Glu-<italic>meso</italic>-Dap-<sc>d</sc>-Ala-<sc>d</sc>-Ala (UK-BaCWAN, University of Warwick) as a substrate. The release of <sc>d</sc>-Ala was followed spectrophotometrically at 510 nm with a <sc>d</sc>-amino acid oxidase&#x02013;peroxidase coupled reaction. Reaction mixtures contained 5 mM of the peroxidase colorimetric substrate 4-aminoantipyrine (Sigma-Aldrich), 3 U/mL <sc>d</sc>-amino acid oxidase (Sigma-Aldrich), 7.5 U/mL horseradish peroxidase (Sigma-Aldrich), and 6 mM phenol in 50 mM 1,3-bis[tris(hydroxymethyl)methylamino]propane (pH 7.4) in a final volume of 1 mL, as described in detail in [<xref rid="B36-antibiotics-07-00036" ref-type="bibr">36</xref>]. To compare the <sc>d</sc>,<sc>d</sc>-dipeptidase and <sc>d</sc>,<sc>d</sc>-carboxypeptidase activities in the cytoplasmic and membrane extracts, the activity was expressed as the number of nanomoles of <sc>d</sc>-Ala released from the dipeptide or tripeptide per min per mg of protein in the extract.</p></sec></sec><sec id="sec4-antibiotics-07-00036"><title>4. Conclusions</title><p>By comparing the specificity of induction of VanX and VanY peptidases in three different soil-dwelling actinomycetes, we confirm that <italic>S. coelicolor</italic> has a VanB-phenotype responding to vancomycin but not to teicoplanin or to teicoplanin-like A40926. <italic>S. coelicolor</italic> does not produce any GPA but possessing resistance genes confers it a selective advantage since it shares the ecological niche (soil) with many other GPAs-producing actinomycetes. Interestingly, by a culture-independent approach using molecular probes, it has been recently estimated that the frequency of encountering a vancomycin-type producer in soil is from 2.5 to 5 times higher than for a teicoplanin-like producing actinomycete [<xref rid="B37-antibiotics-07-00036" ref-type="bibr">37</xref>]. In contrast, the teicoplanin producer <italic>A. teichomyceticus</italic> is highly and constitutively resistant to all the GPAs, including its own product. On the contrary, lower resistance in <italic>N. gerenzanensis</italic> is induced either by vancomycin or teicoplanins, and is based on the action of a VanY carboxypeptidase, which in many enterococci and staphylococci plays an unessential and ancillary role in the presence of VanHAX system [<xref rid="B27-antibiotics-07-00036" ref-type="bibr">27</xref>]. Evidently, although producing structurally similar GPAs, <italic>A. teichomyceticus</italic> and <italic>N. gerenzanensis</italic> do not share the same self-resistant mechanism. Previous comparative analyses of their biosynthetic GPA clusters indicated that many A40926 biosynthetic genes are more related to vancomycin-type genes than to their teicoplanin homologs [<xref rid="B38-antibiotics-07-00036" ref-type="bibr">38</xref>]. The production of A40926 and teicoplanin are most likely the result of a convergent evolution rather than originating from the same common ancestor. Although the identity and the role of the putative VanRS-like two-component signal transduction system in <italic>N. gerenzanensis</italic> needs to be investigated, the results of gene swapping between <italic>A. teichomyceticus</italic> and <italic>N. gerenzanensis</italic> indicate that cross-talking of the two-component systems is possible, as previously demonstrated in other actinomycetes [<xref rid="B21-antibiotics-07-00036" ref-type="bibr">21</xref>,<xref rid="B32-antibiotics-07-00036" ref-type="bibr">32</xref>]. Determining the sequences and the protein structures of the putative VanRS two-component system in <italic>N. gerenzanensis</italic> may help to confirm that the inducer specificity is determined by the origin of VanRS proteins and may provide additional evidence on the role of GPAs as VanS effector ligands. Additionally, since the genes involved in GPAs resistance in pathogens have been recruited from the different antibiotic-producing actinomycetes, gene swapping among different GPA-producing actinomycetes is proving to be useful for unveiling the specificity of regulation and predicting the evolution of future resistance gene combinations emerging in pathogens.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by public grants &#x0201c;Fondo di Ateneo per la Ricerca&#x0201d; 2015, 2016, 2017 to F. Marinelli and G.L. Marcone and by Federation of European Microbiological Societies (FEMS) Research Fellowship 2015 to E. Binda.</p></ack><app-group><app id="app1-antibiotics-07-00036"><title>Supplementary Materials</title><p>The following are available online at <uri xlink:href="http://www.mdpi.com/2079-6382/7/2/36/s1">http://www.mdpi.com/2079-6382/7/2/36/s1</uri>, Table S1: Maximum VanX and VanY activities during the growth (in the absence of GPAs) of <italic>S</italic>. <italic>coelicolor</italic>, <italic>S</italic>. <italic>coelicolor</italic> &#x00394;<italic>vanRS</italic>, <italic>A</italic>. <italic>teichomyceticus</italic>, <italic>N</italic>. <italic>gerenzanensis</italic> and <italic>N</italic>. <italic>gerenzanensis</italic> pST30. The values represent the average of the data from three independent experiments, Table S2: MICs of GPAs in noninduced and teicoplanins-induced actinomycetes. The values represent the average of the data from three independent experiments. </p><supplementary-material content-type="local-data" id="antibiotics-07-00036-s001"><media xlink:href="antibiotics-07-00036-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>E.B., F.M. and G.L.M. conceived and designed the experiments; E.B. and P.C. performed the experiments; E.B., P.C. and G.L.M. analyzed the data; E.B., F.M. and G.L.M. wrote the paper.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-antibiotics-07-00036"><label>1.</label><element-citation publication-type="web"><article-title>European Centre for Disease Prevention and Control</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://ecdc.europa.eu/en/about-us/partnerships-and-networks/disease-and-laboratoy-networks/ears-net">https://ecdc.europa.eu/en/about-us/partnerships-and-networks/disease-and-laboratoy-networks/ears-net</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2018-01-16">(accessed on 16 January 2018)</date-in-citation></element-citation></ref><ref id="B2-antibiotics-07-00036"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binda</surname><given-names>E.</given-names></name><name><surname>Marinelli</surname><given-names>F.</given-names></name><name><surname>Marcone</surname><given-names>G.L.</given-names></name></person-group><article-title>Old and new glycopeptide antibiotics: Action and resistance</article-title><source>Antibiotics</source><year>2014</year><volume>3</volume><fpage>572</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.3390/antibiotics3040572</pub-id><?supplied-pmid 27025757?><pub-id pub-id-type="pmid">27025757</pub-id></element-citation></ref><ref id="B3-antibiotics-07-00036"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcone</surname><given-names>G.L.</given-names></name><name><surname>Binda</surname><given-names>E.</given-names></name><name><surname>Berini</surname><given-names>F.</given-names></name><name><surname>Marinelli</surname><given-names>F.</given-names></name></person-group><article-title>Old and new glycopeptide antibiotics: From product to gene and back in the post-genomic era</article-title><source>Biotechnol. Adv.</source><year>2018</year><volume>36</volume><fpage>534</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1016/j.biotechadv.2018.02.009</pub-id><?supplied-pmid 29454983?><pub-id pub-id-type="pmid">29454983</pub-id></element-citation></ref><ref id="B4-antibiotics-07-00036"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Bambeke</surname><given-names>F.</given-names></name></person-group><article-title>Lipoglycopeptide antibacterial agents in Gram-positive infections: A comparative review</article-title><source>Drugs</source><year>2015</year><volume>18</volume><fpage>2073</fpage><lpage>2095</lpage><pub-id pub-id-type="doi">10.1007/s40265-015-0505-8</pub-id><?supplied-pmid 26603874?><pub-id pub-id-type="pmid">26603874</pub-id></element-citation></ref><ref id="B5-antibiotics-07-00036"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cooper</surname><given-names>M.A.</given-names></name><name><surname>Williams</surname><given-names>D.H.</given-names></name></person-group><article-title>Binding of glycopeptide antibiotics to a model of a vancomycin-resistant bacterium</article-title><source>Chem. Biol.</source><year>1999</year><volume>6</volume><fpage>891</fpage><lpage>899</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(00)80008-3</pub-id><pub-id pub-id-type="pmid">10631517</pub-id></element-citation></ref><ref id="B6-antibiotics-07-00036"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perkins</surname><given-names>H.R.</given-names></name><name><surname>Nieto</surname><given-names>M.</given-names></name></person-group><article-title>The chemical basis for the action of the vancomycin group of antibiotics</article-title><source>Ann. N. Y. Acad. Sci.</source><year>1974</year><volume>235</volume><fpage>348</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1974.tb43276.x</pub-id><?supplied-pmid 4369274?><pub-id pub-id-type="pmid">4369274</pub-id></element-citation></ref><ref id="B7-antibiotics-07-00036"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>N.E.</given-names></name><name><surname>Nicas</surname><given-names>T.I.</given-names></name></person-group><article-title>Mechanism of action of oritavancin and related glycopeptide antibiotics</article-title><source>FEMS Microbiol. Rev.</source><year>2003</year><volume>26</volume><fpage>511</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1111/j.1574-6976.2003.tb00628.x</pub-id><?supplied-pmid 12586393?><pub-id pub-id-type="pmid">12586393</pub-id></element-citation></ref><ref id="B8-antibiotics-07-00036"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trevi&#x000f1;o</surname><given-names>J.</given-names></name><name><surname>Bay&#x000f3;n</surname><given-names>C.</given-names></name><name><surname>Ard&#x000e1;</surname><given-names>A.</given-names></name><name><surname>Marinelli</surname><given-names>F.</given-names></name><name><surname>Gandolfi</surname><given-names>R.</given-names></name><name><surname>Molinari</surname><given-names>F.</given-names></name><name><surname>Jimenez-Barbero</surname><given-names>J.</given-names></name><name><surname>Hern&#x000e1;iz</surname><given-names>M.J.</given-names></name></person-group><article-title>New insights into glycopeptide antibiotic binding to cell wall precursors using SPR and NMR spectroscopy</article-title><source>Chemistry</source><year>2014</year><volume>20</volume><fpage>7363</fpage><lpage>7372</lpage><pub-id pub-id-type="doi">10.1002/chem.201303310</pub-id><?supplied-pmid 24805824?><pub-id pub-id-type="pmid">24805824</pub-id></element-citation></ref><ref id="B9-antibiotics-07-00036"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>S.D.</given-names></name><name><surname>Oberth&#x000fc;r</surname><given-names>M.</given-names></name><name><surname>Losey</surname><given-names>H.C.</given-names></name><name><surname>Anderson</surname><given-names>J.W.</given-names></name><name><surname>Eggert</surname><given-names>U.S.</given-names></name><name><surname>Peczuh</surname><given-names>M.W.</given-names></name><name><surname>Walsh</surname><given-names>C.T.</given-names></name><name><surname>Kahne</surname><given-names>D.</given-names></name></person-group><article-title>The structural basis for induction of VanB resistance</article-title><source>J. Am. Chem. Soc.</source><year>2002</year><volume>124</volume><fpage>9064</fpage><lpage>9065</lpage><pub-id pub-id-type="doi">10.1021/ja026342h</pub-id><?supplied-pmid 12149006?><pub-id pub-id-type="pmid">12149006</pub-id></element-citation></ref><ref id="B10-antibiotics-07-00036"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwun</surname><given-names>M.J.</given-names></name><name><surname>Hong</surname><given-names>H.J.</given-names></name></person-group><article-title>The activity of glycopeptide antibiotics against resistant bacteria correlates with their ability to induce the resistance system</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>6306</fpage><lpage>6310</lpage><pub-id pub-id-type="doi">10.1128/AAC.03668-14</pub-id><?supplied-pmid 25092694?><pub-id pub-id-type="pmid">25092694</pub-id></element-citation></ref><ref id="B11-antibiotics-07-00036"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugg</surname><given-names>T.D.</given-names></name><name><surname>Wright</surname><given-names>G.D.</given-names></name><name><surname>Dutka-Malen</surname><given-names>S.</given-names></name><name><surname>Arthur</surname><given-names>M.</given-names></name><name><surname>Courvalin</surname><given-names>P.</given-names></name><name><surname>Walsh</surname><given-names>C.T.</given-names></name></person-group><article-title>Molecular basis for vancomycin resistance in <italic>Enterococcus faecium</italic> BM4147: Biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA</article-title><source>Biochemistry</source><year>1991</year><volume>30</volume><fpage>10408</fpage><lpage>10415</lpage><pub-id pub-id-type="doi">10.1021/bi00107a007</pub-id><?supplied-pmid 1931965?><pub-id pub-id-type="pmid">1931965</pub-id></element-citation></ref><ref id="B12-antibiotics-07-00036"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arthur</surname><given-names>M.</given-names></name><name><surname>Quintiliani</surname><given-names>R.</given-names></name></person-group><article-title>Regulation of VanA- and VanB-type glycopeptide resistance in enterococci</article-title><source>Antimicrob. Agents Chemother.</source><year>2001</year><volume>45</volume><fpage>375</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1128/AAC.45.2.375-381.2001</pub-id><?supplied-pmid 11158729?><pub-id pub-id-type="pmid">11158729</pub-id></element-citation></ref><ref id="B13-antibiotics-07-00036"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evers</surname><given-names>S.</given-names></name><name><surname>Courvalin</surname><given-names>P.</given-names></name></person-group><article-title>Regulation of VanB-type vancomycin resistance gene expression by the VanS(B)-VanR(B) two-component regulatory system in <italic>Enterococcus faecalis</italic> V583</article-title><source>J. Bacteriol.</source><year>1996</year><volume>178</volume><fpage>1302</fpage><lpage>1309</lpage><pub-id pub-id-type="doi">10.1128/jb.178.5.1302-1309.1996</pub-id><?supplied-pmid 8631706?><pub-id pub-id-type="pmid">8631706</pub-id></element-citation></ref><ref id="B14-antibiotics-07-00036"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>H.J.</given-names></name><name><surname>Hutchings</surname><given-names>M.I.</given-names></name><name><surname>Buttner</surname><given-names>M.J.</given-names></name></person-group><article-title>Vancomycin resistance VanS/VanR two-component systems</article-title><source>Adv. Exp. Med. Biol.</source><year>2008</year><volume>631</volume><fpage>200</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1007/978-0-387-78885-2_14</pub-id><?supplied-pmid 18792691?><pub-id pub-id-type="pmid">18792691</pub-id></element-citation></ref><ref id="B15-antibiotics-07-00036"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Depardieu</surname><given-names>F.</given-names></name><name><surname>Podglajen</surname><given-names>I.</given-names></name><name><surname>Leclercq</surname><given-names>R.</given-names></name><name><surname>Collatz</surname><given-names>E.</given-names></name><name><surname>Courvalin</surname><given-names>P.</given-names></name></person-group><article-title>Modes and modulations of antibiotic resistance gene expression</article-title><source>Clin. Microbiol. Rev.</source><year>2007</year><volume>20</volume><fpage>79</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1128/CMR.00015-06</pub-id><?supplied-pmid 17223624?><pub-id pub-id-type="pmid">17223624</pub-id></element-citation></ref><ref id="B16-antibiotics-07-00036"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwun</surname><given-names>M.J.</given-names></name><name><surname>Novotna</surname><given-names>G.</given-names></name><name><surname>Hesketh</surname><given-names>A.R.</given-names></name><name><surname>Hill</surname><given-names>L.</given-names></name><name><surname>Hong</surname><given-names>H.J.</given-names></name></person-group><article-title>In vivo studies suggest that induction of VanS-dependent vancomycin resistance requires binding of the drug to <sc>d</sc>-Ala-<sc>d</sc>-Ala termini in the peptidoglycan cell wall</article-title><source>Antimicrob. Agents Chemother.</source><year>2013</year><volume>57</volume><fpage>4470</fpage><lpage>4480</lpage><pub-id pub-id-type="doi">10.1128/AAC.00523-13</pub-id><?supplied-pmid 23836175?><pub-id pub-id-type="pmid">23836175</pub-id></element-citation></ref><ref id="B17-antibiotics-07-00036"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koteva</surname><given-names>K.</given-names></name><name><surname>Hong</surname><given-names>H.J.</given-names></name><name><surname>Wang</surname><given-names>X.D.</given-names></name><name><surname>Nazi</surname><given-names>I.</given-names></name><name><surname>Hughes</surname><given-names>D.</given-names></name><name><surname>Naldrett</surname><given-names>M.J.</given-names></name><name><surname>Buttner</surname><given-names>M.J.</given-names></name><name><surname>Wright</surname><given-names>G.D.</given-names></name></person-group><article-title>A vancomycin photoprobe identifies the histidine kinase VanSsc as a vancomycin receptor</article-title><source>Nat. Chem. Biol.</source><year>2010</year><volume>6</volume><fpage>327</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1038/nchembio.350</pub-id><?supplied-pmid 20383152?><pub-id pub-id-type="pmid">20383152</pub-id></element-citation></ref><ref id="B18-antibiotics-07-00036"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>B.P.</given-names></name><name><surname>Selva</surname><given-names>E.</given-names></name><name><surname>Gastaldo</surname><given-names>L.</given-names></name><name><surname>Berti</surname><given-names>M.</given-names></name><name><surname>Pallanza</surname><given-names>R.</given-names></name><name><surname>Ripamonti</surname><given-names>F.</given-names></name><name><surname>Ferrari</surname><given-names>P.</given-names></name><name><surname>Denaro</surname><given-names>M.</given-names></name><name><surname>Arioli</surname><given-names>V.</given-names></name><name><surname>Cassani</surname><given-names>G.</given-names></name></person-group><article-title>A40926, a new glycopeptide antibiotic with anti-<italic>Neisseria</italic> activity</article-title><source>Antimicrob. Agents Chemother.</source><year>1987</year><volume>31</volume><fpage>1961</fpage><lpage>1966</lpage><pub-id pub-id-type="doi">10.1128/AAC.31.12.1961</pub-id><?supplied-pmid 2964225?><pub-id pub-id-type="pmid">2964225</pub-id></element-citation></ref><ref id="B19-antibiotics-07-00036"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dalmastri</surname><given-names>C.</given-names></name><name><surname>Gastaldo</surname><given-names>L.</given-names></name><name><surname>Marcone</surname><given-names>G.L.</given-names></name><name><surname>Binda</surname><given-names>E.</given-names></name><name><surname>Congiu</surname><given-names>T.</given-names></name><name><surname>Marinelli</surname><given-names>F.</given-names></name></person-group><article-title>Classification of <italic>Nonomuraea</italic> sp. ATCC 39727, an actinomycete that produces the glycopeptide antibiotic A40926, as <italic>Nonomuraea gerenzanensis</italic> sp. nov</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>2016</year><volume>66</volume><fpage>912</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1099/ijsem.0.000810</pub-id><?supplied-pmid 26944798?><pub-id pub-id-type="pmid">26944798</pub-id></element-citation></ref><ref id="B20-antibiotics-07-00036"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Argenio</surname><given-names>V.</given-names></name><name><surname>Petrillo</surname><given-names>M.</given-names></name><name><surname>Pasanisi</surname><given-names>D.</given-names></name><name><surname>Pagliarulo</surname><given-names>C.</given-names></name><name><surname>Colicchio</surname><given-names>R.</given-names></name><name><surname>Tal&#x000e0;</surname><given-names>A.</given-names></name><name><surname>de Biase</surname><given-names>M.S.</given-names></name><name><surname>Zanfardino</surname><given-names>M.</given-names></name><name><surname>Scolamiero</surname><given-names>E.</given-names></name><name><surname>Pagliuca</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The complete 12&#x02009;Mb genome and transcriptome of <italic>Nonomuraea gerenzanensis</italic> with new insights into its duplicated &#x0201c;Magic&#x0201d; RNA polymerase</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1038/s41598-016-0025-0</pub-id><?supplied-pmid 28442708?><pub-id pub-id-type="pmid">28442708</pub-id></element-citation></ref><ref id="B21-antibiotics-07-00036"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutchings</surname><given-names>M.I.</given-names></name><name><surname>Hong</surname><given-names>H.J.</given-names></name><name><surname>Buttner</surname><given-names>M.J.</given-names></name></person-group><article-title>The vancomycin resistance VanRS two-component signal transduction system of <italic>Streptomyces coelicolor</italic></article-title><source>Mol. Microbiol.</source><year>2006</year><volume>59</volume><fpage>923</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2005.04953.x</pub-id><?supplied-pmid 16420361?><pub-id pub-id-type="pmid">16420361</pub-id></element-citation></ref><ref id="B22-antibiotics-07-00036"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siewert</surname><given-names>G.</given-names></name><name><surname>Strominger</surname><given-names>J.L.</given-names></name></person-group><article-title>Bacitracin: An inhibitor of the dephosphorylation of lipid pyrophosphate, an intermediate in the biosynthesis of the peptidoglycan of bacterial cell walls</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1967</year><volume>57</volume><fpage>767</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1073/pnas.57.3.767</pub-id><?supplied-pmid 16591529?><pub-id pub-id-type="pmid">16591529</pub-id></element-citation></ref><ref id="B23-antibiotics-07-00036"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamburger</surname><given-names>J.B.</given-names></name><name><surname>Hoertz</surname><given-names>A.J.</given-names></name><name><surname>Lee</surname><given-names>A.</given-names></name><name><surname>Senturia</surname><given-names>R.J.</given-names></name><name><surname>McCafferty</surname><given-names>D.G.</given-names></name><name><surname>Loll</surname><given-names>P.J.</given-names></name></person-group><article-title>A crystal structure of a dimer of the antibiotic ramoplanin illustrates membrane positioning and a potential lipid II docking interface</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>13759</fpage><lpage>13764</lpage><pub-id pub-id-type="doi">10.1073/pnas.0904686106</pub-id><?supplied-pmid 19666597?><pub-id pub-id-type="pmid">19666597</pub-id></element-citation></ref><ref id="B24-antibiotics-07-00036"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beltrametti</surname><given-names>F.</given-names></name><name><surname>Consolandi</surname><given-names>A.</given-names></name><name><surname>Carrano</surname><given-names>L.</given-names></name><name><surname>Bagatin</surname><given-names>F.</given-names></name><name><surname>Rossi</surname><given-names>R.</given-names></name><name><surname>Leoni</surname><given-names>L.</given-names></name><name><surname>Zennaro</surname><given-names>E.</given-names></name><name><surname>Selva</surname><given-names>E.</given-names></name><name><surname>Marinelli</surname><given-names>F.</given-names></name></person-group><article-title>Resistance to glycopeptide antibiotics in the teicoplanin producer is mediated by <italic>van</italic> gene homologue expression directing the synthesis of a modified cell wall peptidoglycan</article-title><source>Antimicrob. Agents Chemother.</source><year>2007</year><volume>51</volume><fpage>1135</fpage><lpage>1141</lpage><pub-id pub-id-type="doi">10.1128/AAC.01071-06</pub-id><?supplied-pmid 17220405?><pub-id pub-id-type="pmid">17220405</pub-id></element-citation></ref><ref id="B25-antibiotics-07-00036"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcone</surname><given-names>G.L.</given-names></name><name><surname>Binda</surname><given-names>E.</given-names></name><name><surname>Carrano</surname><given-names>L.</given-names></name><name><surname>Bibb</surname><given-names>M.</given-names></name><name><surname>Marinelli</surname><given-names>F.</given-names></name></person-group><article-title>Relationship between glycopeptide production and resistance in the actinomycete <italic>Nonomuraea</italic> sp. ATCC 39727</article-title><source>Antimicrob. Agents Chemother.</source><year>2014</year><volume>58</volume><fpage>5191</fpage><lpage>5201</lpage><pub-id pub-id-type="doi">10.1128/AAC.02626-14</pub-id><?supplied-pmid 24957828?><pub-id pub-id-type="pmid">24957828</pub-id></element-citation></ref><ref id="B26-antibiotics-07-00036"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcone</surname><given-names>G.L.</given-names></name><name><surname>Beltrametti</surname><given-names>F.</given-names></name><name><surname>Binda</surname><given-names>E.</given-names></name><name><surname>Carrano</surname><given-names>L.</given-names></name><name><surname>Foulston</surname><given-names>L.</given-names></name><name><surname>Hesketh</surname><given-names>A.</given-names></name><name><surname>Bibb</surname><given-names>M.</given-names></name><name><surname>Marinelli</surname><given-names>F.</given-names></name></person-group><article-title>Novel mechanism of glycopeptide resistance in the A40926 producer <italic>Nonomuraea</italic> sp. ATCC 39727</article-title><source>Antimicrob. Agents Chemother.</source><year>2010</year><volume>54</volume><fpage>2465</fpage><lpage>2472</lpage><pub-id pub-id-type="doi">10.1128/AAC.00106-10</pub-id><?supplied-pmid 20308385?><pub-id pub-id-type="pmid">20308385</pub-id></element-citation></ref><ref id="B27-antibiotics-07-00036"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arthur</surname><given-names>M.</given-names></name><name><surname>Depardieu</surname><given-names>F.</given-names></name><name><surname>Cabani&#x000e9;</surname><given-names>L.</given-names></name><name><surname>Reynolds</surname><given-names>P.</given-names></name><name><surname>Courvalin</surname><given-names>P.</given-names></name></person-group><article-title>Requirement of the VanY and VanX <sc>d</sc>,<sc>d</sc>-peptidases for glycopeptide resistance in enterococci</article-title><source>Mol. Microbiol.</source><year>1998</year><volume>30</volume><fpage>819</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.1998.01114.x</pub-id><?supplied-pmid 10094630?><pub-id pub-id-type="pmid">10094630</pub-id></element-citation></ref><ref id="B28-antibiotics-07-00036"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serina</surname><given-names>S.</given-names></name><name><surname>Radice</surname><given-names>F.</given-names></name><name><surname>Maffioli</surname><given-names>S.</given-names></name><name><surname>Donadio</surname><given-names>S.</given-names></name><name><surname>Sosio</surname><given-names>M.</given-names></name></person-group><article-title>Glycopeptide resistance determinants from the teicoplanin producer <italic>Actinoplanes teichomyceticus</italic></article-title><source>FEMS Microbiol. Lett.</source><year>2004</year><volume>240</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.femsle.2004.09.017</pub-id><?supplied-pmid 15500981?><pub-id pub-id-type="pmid">15500981</pub-id></element-citation></ref><ref id="B29-antibiotics-07-00036"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcone</surname><given-names>G.L.</given-names></name><name><surname>Carrano</surname><given-names>L.</given-names></name><name><surname>Marinelli</surname><given-names>F.</given-names></name><name><surname>Beltrametti</surname><given-names>F.</given-names></name></person-group><article-title>Protoplast preparation and reversion to the normal filamentous growth in antibiotic-producing uncommon actinomycetes</article-title><source>J. Antibiot.</source><year>2010</year><volume>63</volume><fpage>83</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1038/ja.2009.127</pub-id><?supplied-pmid 20057514?><pub-id pub-id-type="pmid">20057514</pub-id></element-citation></ref><ref id="B30-antibiotics-07-00036"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcone</surname><given-names>G.L.</given-names></name><name><surname>Binda</surname><given-names>E.</given-names></name><name><surname>Reguzzoni</surname><given-names>M.</given-names></name><name><surname>Gastaldo</surname><given-names>L.</given-names></name><name><surname>Dalmastri</surname><given-names>C.</given-names></name><name><surname>Marinelli</surname><given-names>F.</given-names></name></person-group><article-title>Classification of <italic>Actinoplanes</italic> sp. ATCC 33076, an actinomycete that produces the glycolipodepsipeptide antibiotic ramoplanin, as <italic>Actinoplanes ramoplaninifer</italic> sp. nov</article-title><source>Int. J. Syst. Evol. Microbiol.</source><year>2017</year><volume>67</volume><fpage>4181</fpage><lpage>4188</lpage><pub-id pub-id-type="doi">10.1099/ijsem.0.002281</pub-id><?supplied-pmid 28905706?><pub-id pub-id-type="pmid">28905706</pub-id></element-citation></ref><ref id="B31-antibiotics-07-00036"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binda</surname><given-names>E.</given-names></name><name><surname>Marcone</surname><given-names>G.L.</given-names></name><name><surname>Pollegioni</surname><given-names>L.</given-names></name><name><surname>Marinelli</surname><given-names>F.</given-names></name></person-group><article-title>Characterization of VanYn, a novel <sc>d</sc>,<sc>d</sc>-peptidase/<sc>d</sc>,<sc>d</sc>-carboxypeptidase involved in glycopeptide antibiotic resistance in <italic>Nonomuraea</italic> sp. ATCC 39727</article-title><source>FEBS J.</source><year>2012</year><volume>279</volume><fpage>3203</fpage><lpage>3213</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2012.08706.x</pub-id><?supplied-pmid 22788848?><pub-id pub-id-type="pmid">22788848</pub-id></element-citation></ref><ref id="B32-antibiotics-07-00036"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kilian</surname><given-names>R.</given-names></name><name><surname>Frasch</surname><given-names>H.J.</given-names></name><name><surname>Kulik</surname><given-names>A.</given-names></name><name><surname>Wohlleben</surname><given-names>W.</given-names></name><name><surname>Stegmann</surname><given-names>E.</given-names></name></person-group><article-title>The VanRS homologous two-component system VnlRSAb of the glycopeptide producer <italic>Amycolatopsis balhimycina</italic> activates transcription of the <italic>vanHAXSc</italic> genes in <italic>Streptomyces coelicolor</italic>, but not in <italic>A. balhimycina</italic></article-title><source>Microb. Drug Resist.</source><year>2016</year><volume>22</volume><fpage>499</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1089/mdr.2016.0128</pub-id><?supplied-pmid 27420548?><pub-id pub-id-type="pmid">27420548</pub-id></element-citation></ref><ref id="B33-antibiotics-07-00036"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sosio</surname><given-names>M.</given-names></name><name><surname>Stinchi</surname><given-names>S.</given-names></name><name><surname>Beltrametti</surname><given-names>F.</given-names></name><name><surname>Lazzarini</surname><given-names>A.</given-names></name><name><surname>Donadio</surname><given-names>S.</given-names></name></person-group><article-title>The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by <italic>Nonomuraea</italic> species</article-title><source>Chem. Biol.</source><year>2003</year><volume>10</volume><fpage>541</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(03)00120-0</pub-id><pub-id pub-id-type="pmid">12837387</pub-id></element-citation></ref><ref id="B34-antibiotics-07-00036"><label>34.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kieser</surname><given-names>T.</given-names></name><name><surname>Bibb</surname><given-names>M.J.</given-names></name><name><surname>Buttner</surname><given-names>M.J.</given-names></name><name><surname>Chater</surname><given-names>K.F.</given-names></name><name><surname>Hopwood</surname><given-names>D.A.</given-names></name></person-group><source>Practical Streptomyces Genetics</source><publisher-name>The John Innes Foundation</publisher-name><publisher-loc>Norwich, UK</publisher-loc><year>2000</year><isbn>0-7084-0623-8</isbn></element-citation></ref><ref id="B35-antibiotics-07-00036"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taurino</surname><given-names>C.</given-names></name><name><surname>Frattini</surname><given-names>L.</given-names></name><name><surname>Marcone</surname><given-names>G.L.</given-names></name><name><surname>Gastaldo</surname><given-names>L.</given-names></name><name><surname>Marinelli</surname><given-names>F.</given-names></name></person-group><article-title><italic>Actinoplanes teichomyceticus</italic> ATCC 31121 as a cell factory for producing teicoplanin</article-title><source>Microb. Cell Fact.</source><year>2011</year><volume>10</volume><fpage>82</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1186/1475-2859-10-82</pub-id><?supplied-pmid 22008254?><pub-id pub-id-type="pmid">22008254</pub-id></element-citation></ref><ref id="B36-antibiotics-07-00036"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binda</surname><given-names>E.</given-names></name><name><surname>Marcone</surname><given-names>G.L.</given-names></name><name><surname>Berini</surname><given-names>F.</given-names></name><name><surname>Pollegioni</surname><given-names>L.</given-names></name><name><surname>Marinelli</surname><given-names>F.</given-names></name></person-group><article-title><italic>Streptomyces</italic> spp. as efficient expression system for a <sc>d</sc>,<sc>d</sc>-peptidase/<sc>d</sc>,<sc>d</sc>-carboxypeptidase involved in glycopeptide antibiotic resistance</article-title><source>BMC Biotechnol.</source><year>2013</year><volume>13</volume><elocation-id>24</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6750-13-24</pub-id><?supplied-pmid 23497129?><pub-id pub-id-type="pmid">23497129</pub-id></element-citation></ref><ref id="B37-antibiotics-07-00036"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thaker</surname><given-names>M.N.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Spanogiannopoulos</surname><given-names>P.</given-names></name><name><surname>Waglechner</surname><given-names>N.</given-names></name><name><surname>King</surname><given-names>A.M.</given-names></name><name><surname>Medina</surname><given-names>R.</given-names></name><name><surname>Wright</surname><given-names>G.D.</given-names></name></person-group><article-title>Identifying producers of antibacterial compounds by screening for antibiotic resistance</article-title><source>Nat. Biotechnol.</source><year>2013</year><volume>31</volume><fpage>922</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1038/nbt.2685</pub-id><?supplied-pmid 24056948?><pub-id pub-id-type="pmid">24056948</pub-id></element-citation></ref><ref id="B38-antibiotics-07-00036"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donadio</surname><given-names>S.</given-names></name><name><surname>Sosio</surname><given-names>M.</given-names></name><name><surname>Stegmann</surname><given-names>E.</given-names></name><name><surname>Weber</surname><given-names>T.</given-names></name><name><surname>Wohlleben</surname><given-names>W.</given-names></name></person-group><article-title>Comparative analysis and insights into the evolution of gene clusters for glycopeptide antibiotic biosynthesis</article-title><source>Mol. Genet. Genom.</source><year>2005</year><volume>274</volume><fpage>40</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1007/s00438-005-1156-3</pub-id><?supplied-pmid 16007453?><pub-id pub-id-type="pmid">16007453</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="antibiotics-07-00036-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>VanX activity in <italic>S. coelicolor</italic>, <italic>S. coelicolor</italic> &#x00394;<italic>vanRS</italic>, <italic>A. teichomyceticus</italic>, and <italic>N. gerenzanensis</italic> pST30 grown in the absence (dotted line) or in the presence (continuous line) of subinhibitory concentrations of GPAs added at the moment of inoculum (see material and methods). VanX-specific activity is defined as the number of nanomoles of <sc>d</sc>-Ala released by the hydrolysis of <sc>d</sc>-Ala-<sc>d</sc>-Ala dipeptide at 37 &#x000b0;C per minute per milligram of protein contained in cytoplasmic fractions. Symbols represent non-induction (&#x025c7;), induction with vancomycin (&#x025cf;), or teicoplanin (&#x025a0;), or A40926 (&#x025bc;). The values represent the averages from three independent experiments, with a standard deviation of &#x0003c;5%.</p></caption><graphic xlink:href="antibiotics-07-00036-g001"/></fig><fig id="antibiotics-07-00036-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>VanY activity in <italic>N. gerenzanensis</italic> and <italic>N. gerenzanensis</italic> pST30 grown in the absence (dotted line) or in the presence (continuous line) of subinhibitory concentrations of GPAs added at the moment of inoculum (see material and methods). VanY-specific activity is defined as the number of nanomoles of <sc>d</sc>-Ala released by the hydrolysis of N<sub>&#x003b5;</sub>-acetyl-<sc>l</sc>-Lys-<sc>d</sc>-Ala-<sc>d</sc>-Ala tripeptide at 37 &#x000b0;C per minute per milligram of protein contained in membrane extracts. Symbols represent non-induction (&#x025c7;), induction with vancomycin (&#x025cf;), or teicoplanin (&#x025a0;), or A40926 (&#x025bc;). The values represent the averages from three independent experiments, with a standard deviation of &#x0003c;5%.</p></caption><graphic xlink:href="antibiotics-07-00036-g002"/></fig><table-wrap id="antibiotics-07-00036-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">antibiotics-07-00036-t001_Table 1</object-id><label>Table 1</label><caption><p>Minimal inhibitory concentrations (MICs) of glycopeptide antibiotics (GPAs), ramoplanin and bacitracin. The values represent the average of the data from three independent experiments.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Actinomycetes</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vancomycin (&#x000b5;g/mL)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Teicoplanin (&#x000b5;g/mL)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">A40926 (&#x000b5;g/mL)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ramoplanin (&#x000b5;g/mL)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Bacitracin (&#x000b5;g/mL)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>S. coelicolor</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003e;100</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5 &#x000b1; 0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5 &#x000b1; 0.075</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 &#x000b1; 0.045</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 &#x000b1; 0.05</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>S. coelicolor</italic> &#x02206;<italic>vanRS</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">1.25 &#x000b1; 0.03</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5 &#x000b1; 0.02</td><td align="center" valign="middle" rowspan="1" colspan="1">1.5 &#x000b1; 0.02</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 &#x000b1; 0.025</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 &#x000b1; 0.035</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>A. teichomyceticus</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">90 &#x000b1; 4.2</td><td align="center" valign="middle" rowspan="1" colspan="1">20 &#x000b1; 1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">32.5 &#x000b1; 1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">20 &#x000b1; 1</td><td align="center" valign="middle" rowspan="1" colspan="1">20 &#x000b1; 1.15</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1"><italic>N. gerenzanensis</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">20 &#x000b1; 1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9 &#x000b1; 0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">4 &#x000b1; 0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">20 &#x000b1; 1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">20 &#x000b1; 1.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>N. gerenzanensis</italic> pST30</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 &#x000b1; 1.05</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.75 &#x000b1; 0.15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17.5 &#x000b1; 0.875</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 &#x000b1; 1.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 &#x000b1; 1.2</td></tr></tbody></table></table-wrap></floats-group></article>